Women with advanced ovarian cancer who begin treatment with olaparib are more likely to respond to the drug if it has been more than a year since their last round of chemotherapy, according to new research.

Scientists have developed a three-in-one blood test that could transform treatment of advanced prostate cancer through use of precision drugs designed to target mutations in the BRCA genes.

ICR CEO Professor Paul Workman comments on the decision by NICE to reject olaparib for women with BRCA mutated ovarian cancer.